Tag: tissue-engineering

This summary draws only from the supplied synthesis packet and keeps human evidence, preclinical results, and mechanistic findings distinct. Claims are limited to what the cited studies support.

Research Context

• The packet is driven by animal, in vitro, and tissue-engineering studies; it does not include human clinical outcome trials for LR3 IGF-1 or native IGF-1. The packet advises against broad human-efficacy framing.
• Several findings concern native IGF-1 rather than LR3 IGF-1; results are context-dependent across analogue, species, age, route, and delivery format. Findings for IGF-1 and LR3 should not be treated as interchangeable.

Key Takeaway

Published IGF-1 LR3 evidence is primarily preclinical and model-specific. Some studies report biomarker or tissue changes, but there are no human efficacy or safety outcomes in this packet, and translational relevance remains uncertain.

Direct Answer

• Direct human efficacy or safety evidence for IGF-1 LR3 is absent in this packet.
• Preclinical studies report heterogeneous, model-specific effects for LR3 IGF-1 and/or native IGF-1 across growth, metabolism, neuropathology markers, and nerve repair, with outcomes varying by analogue, species, age, route, and delivery construct.
• Mechanistic and structural work supports biological plausibility but does not establish clinical utility. Dosing or safety conclusions for humans are not supported by the packet.

Evidence by Category

Human evidence

• No controlled human clinical trials or direct human-outcome studies for LR3 IGF-1 are included in the packet.
• The packet does not support dosing or generalized safety conclusions for humans.

Animal and tissue-engineering studies (preclinical)

• Growth and gut proliferation (rats; LR3 IGF-1 and/or native IGF-1): Systemic infusion of IGF-1 or LR3 IGF-1 stimulated visceral organ growth and gut tissue proliferation in suckling rats [pubmed:9124573]. These neonatal rat findings are not generalizable to humans.
• Fetal growth (sheep; native IGF-1 vs LR3 IGF-1):
• Native IGF-1 infusion increased organ growth in fetal sheep without evidence of increased placental/fetal nutrient transfer [pubmed:33427051]. This prenatal agricultural model has uncertain relevance to adult human outcomes.
• LR3 IGF-1 did not promote growth in late-gestation growth-restricted fetal sheep [pubmed:39679943]. Model- and condition-specific context limits extrapolation.
• Islet function (sheep; native IGF-1): A 1-week native IGF-1 infusion in late-gestation fetal sheep reduced glucose-stimulated insulin secretion due to an intrinsic islet defect in that model [pubmed:33938236]; implications beyond this prenatal context are unknown.
• Neuropathology marker vs function (mice; LR3 IGF-1, intranasal): Intranasal LR3 IGF-1 promoted amyloid plaque remodeling in male 5XFAD mice but did not preserve cognitive function [pubmed:39610283]. Biomarker changes did not translate to behavioral benefit in this model.
• Peripheral nerve repair (rats; LR3 IGF-1, localized construct): A decellularized Alstroemeria stem-based conduit with GelMA and controlled LR3 IGF-1 release reported enhanced sciatic nerve regeneration in a rat model; effects pertain to this localized tissue-engineering context [pubmed:41015370] and should not be extrapolated to systemic delivery.
• Protein metabolism (cattle; LR3 IGF-1): LR3 IGF-1 affected protein metabolism in beef heifers [pubmed:10370861]; this agricultural model has uncertain human relevance.
• Route- and age-dependent intestinal effects (rats; LR3 IGF-1 and/or native IGF-1):
• LR3 IGF-1 showed preferential intestinal delivery compared with native IGF-1 in preweaning and adult rats [pubmed:12697696]. This rat finding does not establish human oral bioavailability.
• Systemic, but not orogastric, delivery of IGF-1 or LR3 IGF-1 increased intestinal disaccharidase activity in suckling rats [pubmed:9803447]. Lack of effect via the orogastric route in this model should not be overinterpreted for humans.
• Reproductive endpoints (rats; LR3 IGF-1): Older reports describe enhanced superovulatory response with LR3 IGF-1 infusion; methodological detail is limited [crossref:10.1016/S0015-0282(97)84896-0; crossref:10.1016/S0015-0282(97)90811-6]. These findings should be viewed as preliminary.

Applied/analytical and production context

• Recombinant expression approaches (including Pichia pastoris fusions) and physicochemical characterization of LR3 IGF-1 inclusion bodies are reported [crossref:10.1007/s00253-023-12606-0; crossref:10.1021/bp010058x].
• Detection of His-tagged LR3 IGF-1 in an unregulated product is described in an analytical report; this is descriptive and nonclinical [crossref:10.1016/j.ghir.2010.07.001].

Mechanistic and in vitro evidence

• Structure: Solution NMR characterized the structure and backbone dynamics of LR3 IGF-1 [pubmed:10744677].
• Signaling modulation (cell system–specific): N-linked glycosylation in Chinese hamster ovary cells was critical for IGF-1 signaling in that system; this study does not distinguish LR3-specific effects [pubmed:36499281].
• Hematopoietic cell biology: IGF-1 and IGF-binding proteins were involved in proliferation and differentiation of murine bone marrow–derived macrophage precursors in vitro/ex vivo [pubmed:9867252].

Gaps and limits

• No direct human efficacy, safety, dose–response, or durability data for LR3 IGF-1 are included in the packet.
• Findings differ by analogue (native IGF-1 vs LR3 IGF-1), species, age, route, and delivery construct; results from one context do not generalize across models.
• Rat intestinal-delivery findings should not be taken as evidence of human oral bioavailability [pubmed:12697696; pubmed:9803447].
• Changes in disease biomarkers without corresponding functional benefit (e.g., amyloid plaque remodeling without cognitive preservation) leave clinical relevance uncertain [pubmed:39610283].
• Localized tissue-engineering results (e.g., nerve conduit delivery) should not be extrapolated to systemic administration or different indications [pubmed:41015370].
• The product-detection report is descriptive and does not evaluate safety, efficacy, or manufacturing quality [crossref:10.1016/j.ghir.2010.07.001].

FAQ

• Is there human clinical evidence for IGF-1 LR3 in this packet?
• No. The packet includes no controlled human clinical trials or direct human-outcome studies for LR3 IGF-1.
• Does IGF-1 LR3 improve cognition in Alzheimer’s-model mice?
• In male 5XFAD mice, intranasal LR3 IGF-1 remodeled amyloid plaques but did not preserve cognitive function [pubmed:39610283].
• Do rat intestinal-delivery studies imply oral bioavailability in humans?
• No. Preferential intestinal delivery and disaccharidase findings are in rats and do not establish human oral bioavailability [pubmed:12697696; pubmed:9803447].
• Are IGF-1 and LR3 IGF-1 findings interchangeable?
• No. Effects vary by analogue, species, age, route, and delivery construct; results should not be conflated.
• What do prenatal or agricultural models (fetal sheep, heifers) tell us about humans?
• They inform biology in those contexts but have uncertain relevance to adult human outcomes [pubmed:33427051; pubmed:33938236; pubmed:10370861].

References

• IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. https://pubmed.ncbi.nlm.nih.gov/39679943/
• Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. https://pubmed.ncbi.nlm.nih.gov/39610283/
• Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. https://pubmed.ncbi.nlm.nih.gov/41015370/
• Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. https://pubmed.ncbi.nlm.nih.gov/10370861/
• IGF-1 infusion to fetal sheep increases organ growth but not by stimulating nutrient transfer to the fetus. https://pubmed.ncbi.nlm.nih.gov/33427051/
• Reduced glucose-stimulated insulin secretion following a 1-wk IGF-1 infusion in late gestation fetal sheep is due to an intrinsic islet defect. https://pubmed.ncbi.nlm.nih.gov/33938236/
• Preferential intestinal delivery of long[Arg3] insulin-like growth factor (LR3IGF-I) over IGF-I in preweaning and adult rats. https://pubmed.ncbi.nlm.nih.gov/12697696/
• Systemically but not orogastrically delivered insulin-like growth factor (IGF)-I and long [Arg3]IGF-I stimulates intestinal disaccharidase activity in two age groups of suckling rats. https://pubmed.ncbi.nlm.nih.gov/9803447/
• N-Linked Glycosylation in Chinese Hamster Ovary Cells Is Critical for Insulin-like Growth Factor 1 Signaling. https://pubmed.ncbi.nlm.nih.gov/36499281/
• Involvement of insulin-like growth factor-1 and its binding proteins in proliferation and differentiation of murine bone marrow-derived macrophage precursors. https://pubmed.ncbi.nlm.nih.gov/9867252/
• Systemic infusion of IGF-I or LR(3)IGF-I stimulates visceral organ growth and proliferation of gut tissues in suckling rats. https://pubmed.ncbi.nlm.nih.gov/9124573/
• Solution structure and backbone dynamics of long-[Arg(3)]insulin-like growth factor-I. https://pubmed.ncbi.nlm.nih.gov/10744677/
• In Vivo Infusion With IGF-I Analogue, Long Arg3-Insulin-Like Growth Factor-I (LR3-IGF-I) Enhances Superovulatory Response in Rats. https://doi.org/10.1016/s0015-0282(97)84896-0
• O-179 In vivo infusion with IGF-I analogue, long Arg3-insulin-like growth factor-I (LR3-IGF-I) enhances superovulatory response in rats. https://doi.org/10.1016/S0015-0282(97)90811-6
• Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. https://doi.org/10.1007/s00253-023-12606-0
• Physicochemical Characteristics of LR3-IGF1 Protein Inclusion Bodies: Electrophoretic Mobility Studies. https://doi.org/10.1021/bp010058x
• Detection of His-tagged Long-R3-IGF-I in a black market product. https://doi.org/10.1016/j.ghir.2010.07.001